论文部分内容阅读
目的探讨神经发育疗法(NDT)对脑瘫患儿具有脑保护作用的转化生长因子β1(TGF-β1)和神经重塑的影响。方法采取自身前后对照的方法,应用双抗体夹心酶联免疫吸附试验法(ABC-ELISA法)分别检测NDT治疗前后脑瘫组血清TGF-β1的水平,同时在NDT治疗前后采用粗大运动功能测试量表(GMFM)对患儿粗大运动进行量化评估。结果脑瘫组NDT治疗前血清TGF-β1水平明显低于脑瘫对照组(P<0.01),脑瘫组NDT治疗后血清TGF-β1明显高于治疗前和脑瘫对照组(P<0.01);脑瘫组NDT治疗前GMFM-88项分值明显低于治疗后(P<0.01);脑瘫组NDT治疗后≤三岁脑瘫组GMFM-88项提高值明显高于>三岁脑瘫组。结论 TGF-β1水平和GMFM能够更加全面客观评价NDT疗效,为脑瘫早期干预和神经康复计划提供依据和治疗方案。
Objective To investigate the effects of neurodevelopmental therapy (NDT) on the expression of transforming growth factor β1 (TGF-β1) and neural remodeling in children with cerebral palsy. Methods Before and after treatment with NDT, the levels of serum TGF-β1 in patients with cerebral palsy before and after NDT were detected by double-antibody sandwich enzyme-linked immunosorbent assay (ABC-ELISA), and the gross motor function test scale (GMFM) to quantify children’s gross motor exercise. Results The level of TGF-β1 in cerebral palsy group was significantly lower than that in cerebral palsy group (P <0.01), and the level of TGF-β1 in ND group was significantly higher than that before treatment and cerebral palsy control group (P <0.01) The score of GMFM-88 before treatment was significantly lower than that after treatment (P <0.01). The improvement of GMFM-88 in patients with cerebral palsy before and after treatment of NDT was significantly higher than that of> three-year-old cerebral palsy group. Conclusion The levels of TGF-β1 and GMFM can evaluate the efficacy of NDT in a more comprehensive and objective way and provide the basis and treatment plan for the early intervention and rehabilitation programs of cerebral palsy.